Today: 21 May 2026
Browse Category

NASDAQ:INTU 2 January 2026 - 23 January 2026

Intuit stock jumps, then cools after hours as TurboTax owner heads into tax-season test

Intuit stock jumps, then cools after hours as TurboTax owner heads into tax-season test

Intuit shares rose 4.3% to $547.69 Thursday, then slipped 0.4% after hours as investors eyed the Jan. 26 IRS tax filing season kickoff. The company reported first-quarter fiscal 2026 revenue of $3.89 billion, beating expectations. Morgan Stanley reiterated its “buy” rating and $880 price target. Intuit stock remains down 17% for the month.
Intuit stock (INTU) rebounds 3% after slide as Morgan Stanley flags TurboTax, QuickBooks growth runway

Intuit stock (INTU) rebounds 3% after slide as Morgan Stanley flags TurboTax, QuickBooks growth runway

Intuit shares rose 3.3% to $542.10 by midday Thursday, rebounding from recent lows as traders focused on tax-season demand and upcoming earnings. Morgan Stanley cited a “credible path to 20% growth” driven by mid-market accounting and assisted tax expansion. The S&P 500 ETF gained 0.8%, while the Nasdaq-100 rose 0.9%. Wells Fargo recently downgraded Intuit and cut its price target to $700.
22 January 2026
Intuit stock price dips again as Morgan Stanley maps a “Triple Double” path for INTU

Intuit stock price dips again as Morgan Stanley maps a “Triple Double” path for INTU

Intuit shares fell 0.6% to $525.93 in late morning trading Wednesday, following a 3% drop Tuesday. Morgan Stanley issued a bullish note, projecting potential doubling in value by 2030, citing growth in mid-market accounting and TurboTax Live. Investors are watching the annual stockholder meeting on Jan. 22 and quarter-end results on Jan. 31. The stock trades about 35% below its July 52-week high.
21 January 2026
‘No reasons to own’? AI agent fears slam software stocks after Anthropic’s Claude Cowork debut

‘No reasons to own’? AI agent fears slam software stocks after Anthropic’s Claude Cowork debut

A Morgan Stanley basket tracking SaaS stocks has fallen about 15% in 2026 after an 11% drop last year, hitting its lowest valuation ever. Intuit plunged 16% last week, while Adobe and Salesforce lost over 11% amid fears Anthropic’s new AI agent, Claude Cowork, could disrupt subscription software models. The Nasdaq 100 remains near record highs, but major software names have slid to multi-year lows.

Stock Market Today

  • Scotiabank Shares Showing 32% Undervaluation at C$108 Amid Strong Returns
    May 20, 2026, 10:05 PM EDT. Scotiabank (TSX:BNS) stock has rallied to around C$108.50, delivering a 59.4% return over the past year and nearly 79% over five years highlighting strong performance. Despite this, valuation models suggest substantial remaining upside. Simply Wall St's Excess Returns analysis estimates the bank's intrinsic value at approximately C$160 per share, indicating it is 32.2% undervalued compared to current prices. This model calculates excess returns by comparing the bank's return on equity to its cost of equity, reflecting efficient shareholder profit generation. Investors are closely watching key fundamentals including balance sheet resilience and dividend yield as Scotiabank navigates evolving interest rate environments. The stock's valuation score of 4 out of 6 suggests moderate confidence among analysts that price gains can continue.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop